Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies.

Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M.

Oncotarget. 2018 Oct 2;9(77):34567-34581. doi: 10.18632/oncotarget.26179. eCollection 2018 Oct 2.

2.

Translating Metabolic Reprogramming into New Targets for Kidney Cancer.

Abu Aboud O, Weiss RH.

Kidney Cancer. 2017 Nov 27;1(2):93-97. doi: 10.3233/KCA-170014.

3.

Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis.

Trott JF, Hwang VJ, Ishimaru T, Chmiel K, Zhou X, Shim K, Stewart B, Mahjoub MR, Jen KY, Barupal D, Li X, Weiss RH.

Am J Physiol Renal Physiol. 2018 Oct 3. doi: 10.1152/ajprenal.00025.2018. [Epub ahead of print]

PMID:
30280600
4.

Management of the Incidental Kidney Mass in the Nephrology Clinic.

Hu SL, Weiss RH.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1407-1409. doi: 10.2215/CJN.00860118. Epub 2018 Apr 13. No abstract available.

PMID:
29653957
5.

Metabolomics and Metabolic Reprogramming in Kidney Cancer.

Weiss RH.

Semin Nephrol. 2018 Mar;38(2):175-182. doi: 10.1016/j.semnephrol.2018.01.006. Review.

PMID:
29602399
6.

The role of nephrologists in the management of small renal masses.

Hu SL, Weiss RH.

Nat Rev Nephrol. 2018 Apr;14(4):211-212. doi: 10.1038/nrneph.2018.10. Epub 2018 Feb 5. No abstract available.

7.

The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation.

Bianchi C, Meregalli C, Bombelli S, Di Stefano V, Salerno F, Torsello B, De Marco S, Bovo G, Cifola I, Mangano E, Battaglia C, Strada G, Lucarelli G, Weiss RH, Perego RA.

Oncotarget. 2017 Dec 8;8(69):113502-113515. doi: 10.18632/oncotarget.23056. eCollection 2017 Dec 26.

8.

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.

PMID:
29207896
9.

The Presented Evidence to Support Symptomatic Hypovolemic-Associated EAH Is Not Convincing.

Hoffman MD, Weiss RH.

Curr Sports Med Rep. 2017 Nov/Dec;16(6):464-466. doi: 10.1249/JSR.0000000000000420. No abstract available.

PMID:
29135648
10.

Glutamine Addiction in Kidney Cancer Suppresses Oxidative Stress and Can Be Exploited for Real-Time Imaging.

Abu Aboud O, Habib SL, Trott J, Stewart B, Liang S, Chaudhari AJ, Sutcliffe J, Weiss RH.

Cancer Res. 2017 Dec 1;77(23):6746-6758. doi: 10.1158/0008-5472.CAN-17-0930. Epub 2017 Oct 11.

PMID:
29021138
11.

Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.

Hwang VJ, Zhou X, Chen X, Trott J, Abu Aboud O, Shim K, Dionne LK, Chmiel KJ, Senapedis W, Baloglu E, Mahjoub MR, Li X, Weiss RH.

Kidney Int. 2017 Oct;92(4):922-933. doi: 10.1016/j.kint.2017.03.031. Epub 2017 May 23.

12.

Metabolic reprogramming in clear cell renal cell carcinoma.

Wettersten HI, Aboud OA, Lara PN Jr, Weiss RH.

Nat Rev Nephrol. 2017 Jul;13(7):410-419. doi: 10.1038/nrneph.2017.59. Epub 2017 May 8. Review.

PMID:
28480903
13.

GHetting to know ADPKD proliferative signaling, STAT.

Chen CH, Weiss RH.

Kidney Int. 2017 Mar;91(3):524-526. doi: 10.1016/j.kint.2016.11.024.

PMID:
28202165
14.

Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Chen CH, Fong LWR, Yu E, Wu R, Trott JF, Weiss RH.

Oncogene. 2017 Jun 22;36(25):3588-3598. doi: 10.1038/onc.2016.510. Epub 2017 Feb 6.

15.
16.

Metabolomic profiling for early cancer detection: current status and future prospects.

Hwang VJ, Weiss RH.

Expert Opin Drug Metab Toxicol. 2016 Sep 23:1-3. [Epub ahead of print] No abstract available.

PMID:
27642860
17.

Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens.

Taylor SL, Ruhaak LR, Weiss RH, Kelly K, Kim K.

Bioinformatics. 2017 Jan 1;33(1):17-25. doi: 10.1093/bioinformatics/btw578. Epub 2016 Sep 4.

18.

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.

Trott JF, Kim J, Abu Aboud O, Wettersten H, Stewart B, Berryhill G, Uzal F, Hovey RC, Chen CH, Anderson K, Graef A, Sarver AL, Modiano JF, Weiss RH.

Oncotarget. 2016 Oct 11;7(41):66540-66557. doi: 10.18632/oncotarget.11658.

19.

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

Abu Aboud O, Chen CH, Senapedis W, Baloglu E, Argueta C, Weiss RH.

Mol Cancer Ther. 2016 Sep;15(9):2119-29. doi: 10.1158/1535-7163.MCT-16-0197. Epub 2016 Jul 7.

21.

The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.

Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH; American Society of Nephrology Onco-Nephrology Forum.

J Am Soc Nephrol. 2016 Aug;27(8):2227-37. doi: 10.1681/ASN.2015121335. Epub 2016 Mar 9. Review.

22.

Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.

Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH.

Mol Cancer Ther. 2016 May;15(5):890-8. doi: 10.1158/1535-7163.MCT-15-0847. Epub 2016 Feb 26.

23.

Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices.

Taylor SL, Ruhaak LR, Kelly K, Weiss RH, Kim K.

Brief Bioinform. 2017 Mar 1;18(2):312-320. doi: 10.1093/bib/bbw010.

24.

Cancers Best Paper Award 2015.

Weiss RH.

Cancers (Basel). 2015 May 29;7(2):963-5. doi: 10.3390/cancers7020818.

25.

Changes in PTGS1 and ALOX12 Gene Expression in Peripheral Blood Mononuclear Cells Are Associated with Changes in Arachidonic Acid, Oxylipins, and Oxylipin/Fatty Acid Ratios in Response to Omega-3 Fatty Acid Supplementation.

Berthelot CC, Kamita SG, Sacchi R, Yang J, Nording ML, Georgi K, Hegedus Karbowski C, German JB, Weiss RH, Hogg RJ, Hammock BD, Zivkovic AM.

PLoS One. 2015 Dec 16;10(12):e0144996. doi: 10.1371/journal.pone.0144996. eCollection 2015.

26.

Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury?

Hoffman MD, Weiss RH.

Clin J Sport Med. 2016 Sep;26(5):417-22. doi: 10.1097/JSM.0000000000000277.

27.

Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21.

Elahi S, Weiss RH, Merani S.

AIDS. 2016 Jan;30(2):171-83. doi: 10.1097/QAD.0000000000000917.

PMID:
26645604
28.

The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.

Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH.

Am J Physiol Renal Physiol. 2015 Sep 15;309(6):F492-8. doi: 10.1152/ajprenal.00238.2015. Epub 2015 Jul 8.

29.

Spontaneous γH2AX Foci in Human Solid Tumor-Derived Cell Lines in Relation to p21WAF1 and WIP1 Expression.

Mirzayans R, Andrais B, Scott A, Wang YW, Weiss RH, Murray D.

Int J Mol Sci. 2015 May 20;16(5):11609-28. doi: 10.3390/ijms160511609.

30.

Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH.

Cancer Res. 2015 Jun 15;75(12):2541-52. doi: 10.1158/0008-5472.CAN-14-1703. Epub 2015 May 7.

31.

PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.

Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH.

Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8. doi: 10.1152/ajpcell.00322.2014. Epub 2015 Mar 25.

32.

On-chip detection of a single nucleotide polymorphism without polymerase amplification.

Han J, Tan M, Sudheendra L, Weiss RH, Kennedy IM.

Nano Res. 2014 Sep 1;7(9):1302-1310.

33.

Biomarkers in IgA nephropathy.

Hwang VJ, Ulu A, van Hoorebeke J, Weiss RH.

Biomark Med. 2014;8(10):1263-77. doi: 10.2217/bmm.14.92. Review.

PMID:
25525986
34.

Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH.

PLoS One. 2014 Dec 2;9(12):e113867. doi: 10.1371/journal.pone.0113867. eCollection 2014.

35.

Biological evaluation of a novel sorafenib analogue, t-CUPM.

Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD.

Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21.

36.

Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.

Tan M, Wettersten HI, Chu K, Huso DL, Watnick T, Friedlander S, Landesman Y, Weiss RH.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1179-86. doi: 10.1152/ajprenal.00406.2014. Epub 2014 Sep 18.

37.

Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis.

Zhang G, Panigrahy D, Hwang SH, Yang J, Mahakian LM, Wettersten HI, Liu JY, Wang Y, Ingham ES, Tam S, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11127-32. doi: 10.1073/pnas.1410432111. Epub 2014 Jul 14.

38.

Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A.

Gupta R, Dong Y, Solomon PD, Wettersten HI, Cheng CJ, Min JN, Henson J, Dogra SK, Hwang SH, Hammock BD, Zhu LJ, Reddel RR, Saltzman WM, Weiss RH, Chang S, Green MR, Wajapeyee N.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3062-71. doi: 10.1073/pnas.1411370111. Epub 2014 Jul 14.

39.

Exercise-associated hyponatremia with exertional rhabdomyolysis: importance of proper treatment.

Hoffman MD, Stuempfle KJ, Sullivan K, Weiss RH.

Clin Nephrol. 2015 Apr;83(4):235-42. doi: 10.5414/CN108233.

PMID:
24931911
40.

Metabolomic profiling of tumor-bearing mice.

Wettersten HI, Ganti S, Weiss RH.

Methods Enzymol. 2014;543:275-96. doi: 10.1016/B978-0-12-801329-8.00014-3.

PMID:
24924138
41.

Symptomatic hypotonic hyponatremia presenting at high altitude.

Hoffman MD, Weiss RH.

Wilderness Environ Med. 2014 Sep;25(3):362-3. doi: 10.1016/j.wem.2014.01.008. Epub 2014 Apr 24. No abstract available.

PMID:
24768570
42.

Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.

Wecksler AT, Hwang SH, Wettersten HI, Gilda JE, Patton A, Leon LJ, Carraway KL 3rd, Gomes AV, Baar K, Weiss RH, Hammock BD.

Anticancer Drugs. 2014 Apr;25(4):433-46. doi: 10.1097/CAD.0000000000000079.

43.

Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment.

Kim K, Mall C, Taylor SL, Hitchcock S, Zhang C, Wettersten HI, Jones AD, Chapman A, Weiss RH.

PLoS One. 2014 Jan 24;9(1):e86223. doi: 10.1371/journal.pone.0086223. eCollection 2014.

44.

Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids.

Nording ML, Yang J, Georgi K, Hegedus Karbowski C, German JB, Weiss RH, Hogg RJ, Trygg J, Hammock BD, Zivkovic AM.

PLoS One. 2013 Oct 24;8(10):e76575. doi: 10.1371/journal.pone.0076575. eCollection 2013.

45.

Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.

Abu Aboud O, Wettersten HI, Weiss RH.

PLoS One. 2013 Aug 7;8(8):e71115. doi: 10.1371/journal.pone.0071115. eCollection 2013.

46.

Stability of miRNA in human urine supports its biomarker potential.

Mall C, Rocke DM, Durbin-Johnson B, Weiss RH.

Biomark Med. 2013 Aug;7(4):623-31. doi: 10.2217/bmm.13.44.

47.

Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations.

Zivkovic AM, Yang J, Georgi K, Hegedus C, Nording ML, O'Sullivan A, German JB, Hogg RJ, Weiss RH, Bay C, Hammock BD.

Metabolomics. 2012 Dec;8(6):1102-1113.

48.

Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer.

Liu R, Wettersten HI, Park SH, Weiss RH.

Future Med Chem. 2013 Jun;5(9):991-4. doi: 10.4155/fmc.13.56. No abstract available.

49.

Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.

Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD.

J Cardiovasc Pharmacol. 2013 Sep;62(3):285-97. doi: 10.1097/FJC.0b013e318298e460.

50.

Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis.

Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, Hammock BD.

Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6530-5. doi: 10.1073/pnas.1304321110. Epub 2013 Apr 3.

Supplemental Content

Loading ...
Support Center